The 21st century has seen an explosion in the availability of all types of data, including healthcare, social media and transactional information. Together, these and other types of large and complex data sets have come to be known as Big Data. The influence of big data within the pharmaceutical industry is still emerging for organizations facing key medical, commercial, and HEOR decisions.

It is important for biopharmaceutical companies attempting to utilize Big Data in their decision-making to not only understand the most valuable data producers but also the most impactful way to disseminate Big Data analyses. This study presents benchmark data on these questions as well as who are the most frequent internal requestors of Big Data analysis and the presence of a Big Data team or function within benchmark participants. Best Practices, LLC utilized medical, commercial and HEOR segmented responses to investigate these issues. The study offers key benchmarks that will help leaders to better understand the growing influence of Big Data in the biopharmaceutical sector and how it impacts medical, HEOR and commercial operations in the U.S.

Majority of Each Segment Rate Internal Groups as Most Impactful Targets for Data Analysis: Internal Commercial, Medical and Development functions were rated by a majority of medical, commercial and HEOR respondents as the most impactful targets for data analysis presentations. A majority of each segment also said these internal groups were also the most frequent requestors of presentations.

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call Benjamin Gregory at 919-767-9160 if you have any questions.